CO5280091A1 - PROTEASE INHIBITORS - Google Patents

PROTEASE INHIBITORS

Info

Publication number
CO5280091A1
CO5280091A1 CO01028467A CO01028467A CO5280091A1 CO 5280091 A1 CO5280091 A1 CO 5280091A1 CO 01028467 A CO01028467 A CO 01028467A CO 01028467 A CO01028467 A CO 01028467A CO 5280091 A1 CO5280091 A1 CO 5280091A1
Authority
CO
Colombia
Prior art keywords
alkyl
het
group
cycloalkyl
mfi
Prior art date
Application number
CO01028467A
Other languages
Spanish (es)
Inventor
Marquis Robert Wells Jr
Daniel Frank Veber
Ru Yu
Scott Kevin Thompson
Dennis Shinji Yamashita
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Priority to CO01028467A priority Critical patent/CO5280091A1/en
Publication of CO5280091A1 publication Critical patent/CO5280091A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto de fórmula I: <EMI FILE="01028467_1" ID="1" IMF=JPEG >En el queR1 se selecciona del grupo formado por:<EMI FILE="01028467_2" ID="2" IMF=JPEG >R2 se selecciona del grupo formado por: H, alquilo C1-6, cicloalquil C3-6-alquilo C0-6, Ar-alquilo C0-6, Het-alquilo C0-6, R9C(O)-, R9C(S)-, R9SO2- R9OC(O)-, R9R11NC(O)-, R9R11NC(S)-, R9(R11)NSO2-<EMI FILE="01028467_3" ID="3" IMF=JPEG >R3 se selecciona del grupo formado por: H, alquilo C1-6, cicloalquil C3-6-alquilo C0-6, alquenilo C2-6, alquinilo C2-6, Het-alquilo C0-6, Ar-alquilo C0-6, Ar-Ar-alquilo C0-6, Ar-Het-alquilo C0-6, Het-Ar-alquilo C0-6 y Het-Het-alquilo C0-6;R3 y R´ pueden estar conectados para formar un anillo de pirrolidina, piperidina o morfolina;R4 se selecciona del grupo formado por H; alquilo C1-6, cicloalquil C3-6-alquilo C0-6, Ar-alquilo C0-6, Het-alquilo C0-6; R5C(O)-, R5C(S)-, R5SO2-, R5OC(O)-, R5R12NC(O)-, y R5R12NC(S)-;R5 se selecciona del grupo formado por H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquil C3-6-alquilo C0-6, alcanoilo C2-6, Ar-alquilo C0-6, y Het-alquilo C0-6; R6 se selecciona del grupo formado por: H, alquilo C1-6, Ar-alquilo C0-6, y Het-alquilo C0-6; R7 se selecciona del grupo formado por: H, alquilo C1-6, cicloalquil C3-6-alquilo C0-6, Ar-alquilo C0-6, Het-alquilo C0-6, R10C(O)-, R10C(S)-, R10SO2-, R10OC(O)-, R10R13NC(O)-, y R10R13NC(S)-;R8 se selecciona del grupo formado por: H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, Het-alquilo C0-6, y Ar-alquilo C0-6;R9 se selecciona del grupo formado por: alquilo C1-6, cicloalquil C3-6-alquilo C0-6, Ar-alquilo C0-6, y Het-alquilo C0-6; - 2 -R10 se selecciona del grupo formado por: alquilo C1-6, cicloalquil C3-6-alquilo C0-6, Ar-alquilo C0-6 y Het-alquilo C0-6;R11 se selecciona del grupo formado por: H, alquilo C1-6, cicloalquil C3-6-alquilo C0-6 Ar-alquilo C0-6, y Het-alquilo C0-6; R12 se selecciona del grupo formado por: H, alquilo C1-6, Ar-alquilo C0-6, Het-alquilo C0-6;R13 se selecciona del grupo formado por: H, alquilo C1-6, Ar-alquilo C0-6, Het-alquilo C0-6;R´ se selecciona del grupo formado por: H, alquilo C1-6, Ar-alquilo C0-6, Het-alquilo C0-6;R´´ se selecciona del grupo formado por: H, alquilo C1-6, Ar-alquilo C0-6, o Het-alquilo C0-6;R´´´ es alquilo C1-6;X se selecciona del grupo formado por: CH2, S y O;Z se selecciona del grupo formado por: C(O) y CH2;n es un número entero de 1 a 5; y sus sales farmacéuticamente aceptables, hidratos y solvatos.A compound of formula I: <EMI FILE = "01028467_1" ID = "1" MFI = JPEG> In which R1 is selected from the group consisting of: <EMI FILE = "01028467_2" ID = "2" MFI = JPEG> R2 is selected from the group consisting of: H, C1-6 alkyl, C3-6 cycloalkyl-C0-6 alkyl, Ar-C0-6 alkyl, Het-C0-6 alkyl, R9C (O) -, R9C (S) -, R9SO2 - R9OC (O) -, R9R11NC (O) -, R9R11NC (S) -, R9 (R11) NSO2- <EMI FILE = "01028467_3" ID = "3" MFI = JPEG> R3 is selected from the group consisting of: H , C1-6 alkyl, C3-6 cycloalkyl-C0-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Het-C0-6 alkyl, Ar-C0-6 alkyl, Ar-Ar-C0-6 alkyl, Ar -Het-C0-6 alkyl, Het-Ar-C0-6 alkyl and Het-Het-C0-6 alkyl; R3 and R´ may be connected to form a pyrrolidine, piperidine or morpholine ring; R4 is selected from the group formed by H; C1-6 alkyl, C3-6 cycloalkyl-C0-6 alkyl, Ar-C0-6 alkyl, Het-C0-6 alkyl; R5C (O) -, R5C (S) -, R5SO2-, R5OC (O) -, R5R12NC (O) -, and R5R12NC (S) -; R5 is selected from the group consisting of H, C1-6 alkyl, C2 alkenyl -6, C2-6 alkynyl, C3-6 cycloalkyl-C0-6 alkyl, C2-6 alkanoyl, Ar-C0-6 alkyl, and Het-C0-6 alkyl; R6 is selected from the group consisting of: H, C1-6 alkyl, Ar-C0-6 alkyl, and Het-C0-6 alkyl; R7 is selected from the group consisting of: H, C1-6 alkyl, C3-6 cycloalkyl-C0-6 alkyl, Ar-C0-6 alkyl, Het-C0-6 alkyl, R10C (O) -, R10C (S) - , R10SO2-, R10OC (O) -, R10R13NC (O) -, and R10R13NC (S) -; R8 is selected from the group consisting of: H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Het- C0-6 alkyl, and Ar-C0-6 alkyl; R9 is selected from the group consisting of: C1-6 alkyl, C3-6 cycloalkyl-C0-6 alkyl, Ar-C0-6 alkyl, and Het-C0-6 alkyl ; - 2 -R10 is selected from the group consisting of: C1-6 alkyl, C3-6 cycloalkyl-C0-6 alkyl, Ar-C0-6 alkyl and Het-C0-6 alkyl; R11 is selected from the group consisting of: H, C1-6 alkyl, C3-6 cycloalkyl-C0-6 alkyl Ar-C0-6 alkyl, and Het-C0-6 alkyl; R12 is selected from the group consisting of: H, C1-6 alkyl, Ar-C0-6 alkyl, Het-C0-6 alkyl; R13 is selected from the group consisting of: H, C1-6 alkyl, Ar-C0-6 alkyl , Het-C0-6 alkyl; R 'is selected from the group consisting of: H, C1-6 alkyl, Ar-C0-6 alkyl, Het-C0-6 alkyl; R´´ is selected from the group consisting of: H, C1-6 alkyl, Ar-C0-6 alkyl, or Het-C0-6 alkyl; R´´´ is C1-6 alkyl; X is selected from the group consisting of: CH2, S and O; Z is selected from the group formed by: C (O) and CH2; n is an integer from 1 to 5; and its pharmaceutically acceptable salts, hydrates and solvates.

CO01028467A 2001-04-10 2001-04-10 PROTEASE INHIBITORS CO5280091A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CO01028467A CO5280091A1 (en) 2001-04-10 2001-04-10 PROTEASE INHIBITORS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CO01028467A CO5280091A1 (en) 2001-04-10 2001-04-10 PROTEASE INHIBITORS

Publications (1)

Publication Number Publication Date
CO5280091A1 true CO5280091A1 (en) 2003-05-30

Family

ID=40953610

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01028467A CO5280091A1 (en) 2001-04-10 2001-04-10 PROTEASE INHIBITORS

Country Status (1)

Country Link
CO (1) CO5280091A1 (en)

Similar Documents

Publication Publication Date Title
AR029614A1 (en) DERIVATIVES OF 4-PHENYL-PYRIDINE, ITS USE, A PROCESS TO PREPARE THEM, AND MEDICATIONS CONTAINING THEM
AR068413A2 (en) 8-AMINO DERIVATIVES, PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THERAPY
ES2182535T3 (en) BENZO DERIVATIVES (B) TIEPINA-1, -DIOXIDE, PROCEDURE FOR PREPARATION, MEDICATIONS CONTAINING THESE COMPOUNDS AND THEIR USE.
CO5140088A1 (en) DERIVATIVES OF FENIL AND PIRIDINIL AMIDA, ITS SYNTHESIS PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UY26727A1 (en) USEFUL TROPANIC DERIVATIVES IN THERAPY
HRP20030003B1 (en) N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
AR044629A1 (en) DERIVATIVES OF BENCIMIDAZOL, COMPOSITIONS THAT CONTAIN THEM, PREPARATION AND USES OF THE SAME.
ES2189502T3 (en) METHOD FOR THE PREVENTION OF CITALOPRAM.
CO5140087A1 (en) DERIVATIVES OF 3-PHENYL-PYRIDINE YOUR SYNTHESIS PROCEDURE AND MEDICINES CONTAINING THEM
EA200201179A1 (en) DERIVATIVES 2-AMINOKARBONIL-9H-PURINA
EA200970493A1 (en) MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS
CO4990929A1 (en) DIFENILUREA COMPOUNDS SUBSTITUTED WITH SULFONAMIDES AS ANTAGONISTS OF IL-8 RECEPTORS
CO5261616A1 (en) NON-PEPTIDIC INHIBITORS OF THE CELLULAR UNION DEPENDENTS OF VLA-4 USEFUL IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND RESPIRATORY DISEASES
PE2799A1 (en) LACTAMS AND HETERO-CYCLIC IMIDES OF ARALQUILO AND ARALQUILIDENO
AR064521A1 (en) GLUCOQUINASE ACTIVATOR
EA200200510A1 (en) 4-CARBOXYAMINO-2-ETHYL-1,2,3,4-TETRAHYDROCHINOLINE IN A CRYSTAL FORM AS A CETR INHIBITOR
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
CO5580821A2 (en) 4-CETOLACTAMAS AND -LACTONES 3-PHENYL-3-SUBSTITUTED, SPIROCYCLES
ES2191963T3 (en) TRICICLIC DERIVATIVES OF TRIAZOLOBENZAZEPINA, PROCESS FOR THE OBTAINING OF THE SAME AND ANTIALERGIC AGENTS.
ATE333457T1 (en) CYCLIC GMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS
CO5160261A1 (en) SUBSTITUTED BIFENYL DERIVATIVES THAT ARE NK-1 ANTAGONISTS, THEIR SYNTHESIS PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ECSP045121A (en) RECEIVER AGONISTS ACTIVATED BY PEROXISOM PROLIFERATOR
CO5180541A1 (en) PROTEASE INHIBITORS OF THE 1,3-DIAMINOCETONE TYPE WITH 8-14 MEMBER RING
CO5280088A1 (en) PROTEASA INHIBITORS
EA200400806A1 (en) METHOD OF OBTAINING ECHINOCANDINE COMPOUNDS

Legal Events

Date Code Title Description
FC Application refused